26804-K. Eristavi National Center of Clinical Surgery
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Urboniene, Audrone
NCT04209543 / 2019-001289-14: Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Completed
3
1570
Europe, Canada, US, RoW
Estetrol, Placebo, Progesterone
Estetra, ICON Clinical Research
Vasomotor Symptoms, Menopausal Symptoms
02/24
02/24
NCT06087640: A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Active, not recruiting
3
35800
Europe, RoW
aQIV or aTIV, Fluad Tetra/Quadrivalent or Fluad, QIV or TIV
Seqirus
Influenza, Human
11/26
12/26
Tafuri, Silvio
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
NCT06087640: A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Active, not recruiting
3
35800
Europe, RoW
aQIV or aTIV, Fluad Tetra/Quadrivalent or Fluad, QIV or TIV
Seqirus
Influenza, Human
11/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Urboniene, Audrone
NCT04209543 / 2019-001289-14: Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Completed
3
1570
Europe, Canada, US, RoW
Estetrol, Placebo, Progesterone
Estetra, ICON Clinical Research
Vasomotor Symptoms, Menopausal Symptoms
02/24
02/24
NCT06087640: A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Active, not recruiting
3
35800
Europe, RoW
aQIV or aTIV, Fluad Tetra/Quadrivalent or Fluad, QIV or TIV
Seqirus
Influenza, Human
11/26
12/26
Tafuri, Silvio
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
NCT06087640: A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Active, not recruiting
3
35800
Europe, RoW
aQIV or aTIV, Fluad Tetra/Quadrivalent or Fluad, QIV or TIV
Seqirus
Influenza, Human
11/26
12/26

Download Options